1. Home
  2. SSRM vs RYTM Comparison

SSRM vs RYTM Comparison

Compare SSRM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SSR Mining Inc.

SSRM

SSR Mining Inc.

HOLD

Current Price

$31.48

Market Cap

6.5B

Sector

Industrials

ML Signal

HOLD

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$86.64

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSRM
RYTM
Founded
1946
2008
Country
United States
United States
Employees
2900
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
5.9B
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SSRM
RYTM
Price
$31.48
$86.64
Analyst Decision
Buy
Strong Buy
Analyst Count
4
14
Target Price
$32.74
$131.14
AVG Volume (30 Days)
4.0M
934.8K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
28.34
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$58.07
$55.17
Revenue Next Year
$3.57
$95.98
P/E Ratio
$14.37
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.65
$45.91
52 Week High
$33.49
$122.20

Technical Indicators

Market Signals
Indicator
SSRM
RYTM
Relative Strength Index (RSI) 61.94 47.22
Support Level $21.71 $84.39
Resistance Level $33.49 $97.19
Average True Range (ATR) 1.78 5.47
MACD 0.54 0.58
Stochastic Oscillator 88.56 46.24

Price Performance

Historical Comparison
SSRM
RYTM

About SSRM SSR Mining Inc.

SSR Mining Inc is a minerals company focused on mining precious metals in the Americas. More than half of Silver Standard's revenue is attributable to the production of gold, with a key portion derived from silver production. The company owns and operates the Marigold mine in Nevada, United States; the Seabee Gold Operation in Saskatchewan, Canada; and the Puna mine in Argentina. The majority of gold production is derived from the Marigold mine, and Silver Standard's silver production is principally derived from the Puna mine.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: